

Disclaimer

This presentation is prepared according to the reviewed financial statements by CPA and the financial numbers hereby are based on IFRS, please refer to the published financial statements for full content.

The presentation may contain forward-looking information and may differ materially from the actual results. DMT does not warranty as to the accuracy or completeness of such information and nor assume any undertaking further information becomes available or in light of changing circumstances. You shall not place undue reliance on any for ward looking information.

The presentation and its contents may not be reproduced to a third party without the prior written consent of DMT.



1. 公司概況(Corporate Overview)


2. 市場概況(Market Overview)

3. 營運概況(Business Overview)


4. 財務概況(Financial Overview)


3






Top Provider of Medical Aesthetic Solutions in Asia











Market Overview

According to the Asian-Pacific Market Study issued by Medical Insight, Inc. in Mar. 2022, total Asian sales of all aesthetic products and equipment reached US\$2.7 billion in 2020 and are expected to increase by 16.4% per year through 2025.

Furthermore, medical aesthetic market can be divided into 4 sections: Energy-Based Device, Body Shaping and Skin Tightening ,Dermal Filler and Neurotoxin, and DMT's distributed products covers all of the sections.











Business Overview

Unit : NTD\$K


DMT Revenue by product ratio






Unit : NTD\$K









Profit Before Income Tax

Net Profit for the year





Future Prospects



✓ Southeast Asia Market

ORMER

- ✓ Strategic Alliance
- ✓ Market leader

Mid-Term Planning


- ✓ New Product Development
 - ✓ Preventive Medicine
 - ✓ Lifestyle Beauty Device
 - ✓ Aesthetic Consumables
- ✓ Body Contouring Market Development
- ✓ Channel Expansion


Short-Term Planning

- ✓ Launching Cosmetic Neurotoxin: Neuronox
- ✓ Launching Muscle Toning Device
- ✓ Hydra touch H2
- ✓ Enhance the Sales of Aesthetic Consumables
- ✓ Brand Expansion

T rechnologies INC.

20










Neuronox

肉毒桿菌素注射劑







2022'S New Arrival




DR CYJ 胜肽恆燦護色系列

永恆璀璨 閃耀光彩


✓針對經常染燙
✓需要護色
✓易毛躁打結
✓無光澤髮所設計



26










Blogger's share







CONSOLIDATED BALANCE SHEETS-1

Unit : NTD\$K	2019/12/31	2020/12/31	2021/12/31
Cash and cash equivalents	681,226	784,901	813,371
Debt investments with no active market - current	468,649	447,351	492,091
Notes receivable & Trade receivables	166,001	134,837	133,539
Inventories	229,816	147,124	170,233
Other current assets	19,759	22,959	33,043
Total current assets	1,565,451	1,537,172	1,642,277
Long-term investment	150,449	152,721	132,655
Property, plant and equipment	134,894	114,499	136,013
Right-of-use asset	171,216	153,364	204,793
Other non-current assets	202,353	185,079	183,053
TOTAL	2,224,363	2,142,835	2,298,791

DMT dynamic medical technologies ind

Unit : NTD\$K	2019/12/31	SHEETS-2 2020/12/31	2021/12/31
Notes payable & Trade payables	58,818		61,554
Other payables	185,019	152,170	134,488
long-term liabilities-current portion	,	,	,
contract liability	295,460	306,505	375,255
Other current liabilities	81,208	69,894	86,258
Total current liabilities	620,505	555,670	657,555
Bonds payable			·
Other non-current liabilities	4,294	5,820	3,172
Lease liabilities - Non related parties	131,353	118,148	166,141
Total liabilities	756,152	679,638	826,868
Ordinary shares	300,000	300,000	300,000
Retained earnings	303,971	319,580	337,807
Capital surplus	627,726	627,726	627,726
Other equity	50,013	43,624	18,509
NON-CONTROLLING INTERESTS	186,501	172,267	187,881
Total equity	1,468,211	1,463,197	1,471,923
TOTAL	2,224,363	2,142,835	2,298,791
The Net Asset Value of Each Share	48.94	48.77	49.06

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

Unit:NTD\$K	2019 2020		2021			
	AMT	%	AMT	%	AMT	%
OPERATING REVENUE	1,178,195	100.00	1,009,308	100.00	1,028,183	100.00
OPERATING COSTS	844,027	71.64	691,266	68.49	673,601	65.51
GROSS PROFIT	334,168	28.36	318,042	31.51	354,582	34.49
OPERATING EXPENSES	176,345	14.97	177,194	17.56	194,164	18.88
PROFIT FROM OPERATIONS	157,823	13.40	140,848	13.95	160,418	15.60
NON-OPERATING INCOME AND EXPENSES	2,152	0.18	7,842	0.78	13,403	1.30
		0.00		0.00		0.00
PROFIT BEFORE INCOME TAX	159,975	13.58	148,690	14.73	173,821	16.91
INCOME TAX EXPENSE	33,903	2.88	32,048	3.18	32,132	3.13
NET PROFIT FOR THE YEAR	126,072	10.70	116,642	11.56	141,689	13.78
OTHER COMPREHENSIVE INCOME	(9,098)	(0.77)	(7,023)	(0.70)	(25,111)	(2.44)
TOTAL COMPREHENSIVE INCOME FOR THE YEAR	116,974	9.93	109,619	10.86	116,578	11.34
NET PROFIT ATTRIBUTABLE TO Owners of the Company	112,521	9.55	115,995	11.49	123,206	11.98
EPS	3.75		3.87		4.11	/ //

CONSOLIDATED STATEMENTS OF CASH FLOWS-1

Unit : NTD\$K	2019	2020	2021	
Cash flows from operating activities:				
Profit before tax	159,975	148,690	173,821	
Total adjustments to reconcile profit	72,554	80,264	88,856	
Accounts receivable	43,993	35,386	(5,416)	
Other receivable	(457)	646	(29)	
Inventories	78,140	63,893	(52,459)	
Accounts payable	(21,036)	(31,717)	34,453	
Other payable	(4,669)	(32,849)	(17,682)	
Income taxes paid	(30,810)	(25,547)	(21,857)	
Other	(30,733)	9,785	77,958	
Net cash flows from operating activities	266,957	248,551	277,645	



CONSOLIDATED STATEMENTS OF CASH FLOWS-2

Unit : NTD\$K	2019	2020	2021
Cash flows from investing activities:			
Acquisition of financial assets at amortised cost	(348,649)	(246,501)	(268,491)
Proceeds from disposal of financial assets at amortised cost	60,000	267,799	223,751
Acquisition investments in debt instrument without active market	-	-	-
Proceeds from disposal of investments in debt instrument without active market		-	-
Proceeds from capital reduction of investments accounted for using equity method		-	
Increase in other financial assets	(7,000)	0	0
Decrease in refundable deposits	(3,139)	(1,890)	2,556
Dividends received	1,859	4,784	2,970
Other	(15,124)	(6,904)	(53,205)
Net cash flows from (used in) investing activities	(312,053)	17,288	(92,419)
WAMIC MEDICAL TECHNOLOGIES INC.			

CONSOLIDATED STATEMENTS OF CASH FLOWS-3

2019	2020	2021
-	-	
(94,500)	(100,500)	(105,000)
-	-	-
(43,417)	(50,943)	(43,680)
(137,917)	(151,443)	(148,680)
(4,646)	(10,721)	(8,076)
(187,659)	103,675	28,470
868,885	681,226	784,901
681,226	784,901	813,371
	(94,500) (94,500) (43,417) (43,417) (137,917) (4,646) (187,659) <u>868,885</u>	(94,500) (100,500) (94,500) (100,500) (43,417) (50,943) (137,917) (151,443) (4,646) (10,721) (187,659) 103,675 <u>868,885</u> <u>681,226</u>

DMT dynamic medical technologies ini

On the Top, Aiming High

Accumulated years of experience, DMT. is in the leading edge of the medical aesthetic market by means of sophisticated sales and marketing forces and dedicated service and management team. With successful integration, DMT has achieved vertical integration of medical aesthetics resources. From importing medical aesthetic products to assisting clinical operations, DMT has created global competitive advantage. We have already positioned ourselves in the Greater China market and will keep making all-out effort to enhance Greater China Medical Aesthetic market. The value created by DMT will be clear for all to see!





┃國際尖端醫美儀器銷售┃醫美儀器維修保養 ┃ 植入式填充劑銷售 ┃ 整合性醫美行銷服務 ┃ 專業健髮系統銷售 ┃

international medical aesthetics equipment selling Medical aesthetics equipment maintenance Dermal filler selling Integrated marketing services for medical aesthetics